AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00259610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: varies
Study NCT00259610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: varies
Study NCT01766596 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optical Coherence Tomography
Study NCT00731627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet a day for up to 21 days
Study NCT00731627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40mg once a day for a maximum of 21 days
Study NCT02518256 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal fallopian tubes
Study NCT01160315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin: intramusculAR injection every 3 months
Study NCT01160315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate
Description: 5 mg/day per os until during chemotherapy
Study NCT01160315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone acetate
Description: 5 mg/day per os until during chemotherapy
Study NCT04926428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: Selectively catheter thrombolysis with alteplase in each main pulmonary
Study NCT01185769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 500 mg of tocotrienol will be administered after consumption of high fat diet
Study NCT01185769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 500 mg of tocotrienol will be administered after consumption of low fat diet
Study NCT02705586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
Study NCT00148369 — intervention group
Intervention type: DRUG
Intervention: Safety observation
Description: Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
Study NCT00117663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: temporary discontinuation of hormone therapy for 1 month
Description: temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
Study NCT00117663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: temporary discontinuation of hormone therapy for 2 months
Description: temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 weeks Dose Induction of Everolimus
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 weeks Conventional Everolimus Dosing
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio
Study NCT01133847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: Nine sessions on parenting a child with ADHD
Study NCT01133847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Salt Amphetamine
Description: Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
Study NCT01133847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Appropriate dosage to be individually determined; daily for 16 weeks
Study NCT01133847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Appropriate dosage to be individually determined; daily for 16 weeks
Study NCT03892096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-based cell-free cfDNA qPCR assay
Description: Up to 30mL of blood via venipuncture
Study NCT00799422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Easy Rub
Description: Commercially marketed contact lens solution for contact lens care
Study NCT00799422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus
Description: Commercially marketed contact lens solution for contact lens care
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
Description: All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
Description: All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care after 24 weeks
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
Study NCT02387099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care after 24 weeks
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
Study NCT02613676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin screening
Description: Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
Study NCT02613676 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care (Visual inspection)
Description: Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
Study NCT03311113 — intervention group
Intervention type: OTHER
Intervention: Drug adherence questionnaire
Description: Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
Study NCT01454661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG
Description: Lactobacillus rhamnosus GG 10E9 cfu / day
Study NCT01454661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG+Bb-12
Description: A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
Study NCT01454661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose is used as placebo.
Study NCT01464736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
Study NCT00004266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Study NCT00004266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Study NCT00004266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT03760835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Description: Treatment of congenital adrenal hyperplasia
Study NCT03760835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Description: Treatment of congenital adrenal hyperplasia
Study NCT03760835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual release hydrocortisone (plenadren)
Description: Treatment of congenital adrenal hyperplasia
Study NCT06509841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation treatment
Description: Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.
Study NCT06509841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional rehabilitation treatment
Description: Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.
Study NCT06509841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment rehabilitation
Description: Routine rehabilitation treatment combined with acupuncture and moxibustion treatment, the acupuncture measures taken are mainly Dumai points. Once a day. 5 times a week, continuous treatment for 4 weeks.
Study NCT06240663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
Study NCT01629186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPO with Nose-close and Abdomen-compression
Description: Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
Study NCT00102063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet, 10 mg
Description: Aripiprazole tablet 10 mg po qd x 42 days
Study NCT00102063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet, 30 mg
Description: Aripiprazole tablet 30 mg po qd x 42 days
Study NCT00102063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet po qd x 42 days
Study NCT02245581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVV-guided fluid management
Study NCT02245581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVP-guided fluid management
Study NCT00413595 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
Study NCT02655835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation
Study NCT02655835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access
Study NCT03707041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P218 (1000 mg) Oral Capsules
Description: 1000 mg P218 (4 x 250 mg capsules)
Study NCT03707041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsules
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste
Study NCT03707041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsules
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste
Study NCT03707041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P218 (100 mg) Oral Capsules
Description: 100 mg P218 (2 x 50 mg capsules)
Study NCT03707041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study NCT03707041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study NCT03707041 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study NCT03123978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT03123978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Given PO
Study NCT03392740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
Study NCT03392740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
Study NCT00094094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
Study NCT01795079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Study NCT01795079 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Study NCT04171713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion + Treatment as usual
Description: Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
Study NCT04171713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy + Treatment as usual
Description: It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
Study NCT04171713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
Study NCT04171713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
Study NCT02156921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App-based training
Study NCT05093465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day.
Study NCT05093465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants were provided with sleep hygiene and stimulus control procedures.
Study NCT04153448 — intervention group
Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
Study NCT03629028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Residual myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
Study NCT03629028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Presence
Description: The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
Study NCT03629028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Adjacent myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
Study NCT03629028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Measurements (depth of niche, width of niche, length of niche)
Description: The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
Study NCT06616428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bike group fitness class
Description: Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
Study NCT06616428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump Power
Description: Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
Study NCT06616428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Training
Description: Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
Study NCT00940602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
Study NCT00940602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
Study NCT01816984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO
Study NCT02034604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Study NCT04068311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Screening tools
Description: Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.